bezafibrate has been researched along with Barth Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chin, MT; Heyman, A; Hornby, B; Jefferies, J; Pu, WT; Takemoto, C; Thompson, R; Vernon, HJ; Wang, S | 1 |
| Glukhov, AV; Huang, Y; James, JF; Javadov, S; Jefferies, JL; Khuchua, Z; Moore, V; Phoon, CK; Powers, C; Ren, M; Schafer, C; Strauss, AW; Vaz, FM | 1 |
1 review(s) available for bezafibrate and Barth Syndrome
| Article | Year |
|---|---|
Current and future treatment approaches for Barth syndrome.
Topics: Acyltransferases; Animals; Barth Syndrome; Bezafibrate; Cardiolipins; Cardiomyopathies; Clinical Trials as Topic; Enzyme Therapy; Genetic Therapy; Humans; Mice; Muscular Diseases; Neutropenia; Oligopeptides; Peroxisome Proliferator-Activated Receptors | 2022 |
1 other study(ies) available for bezafibrate and Barth Syndrome
| Article | Year |
|---|---|
The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome.
Topics: Animals; Barth Syndrome; Bezafibrate; Blotting, Western; Cardiolipins; Cardiomyopathies; Disease Models, Animal; Echocardiography; Female; Male; Mice; Peroxisome Proliferator-Activated Receptors; Polymerase Chain Reaction | 2017 |